Patricia Inacio, PhD, science writer —

The China National Food and Drug Administration has accepted and placed under priority review an application from Remegen seeking approval of telitacicept as a treatment for generalized myasthenia gravis (gMG). That’s according to a press release from Remegen, a commercial-stage biotechnology company that’s developing the treatment…

Among people with myasthenia gravis (MG), the degree of daily activity impairment is greater for those with more severe and more widespread muscle weakness, according to real-world data from a survey of physicians in the U.S. and Europe. However, the study — which involved clinicians treating more than…

Intravenous (into-the-vein) treatment with Argenx’s Vyvgart (efgartigimod alfa) resolved a myasthenic crisis — a life-threatening complication of myasthenia gravis (MG) marked by severe breathing problems — in a 57-year-old man who had failed to respond to prior treatments, according to a case study. The findings…

Adolescent girls with juvenile myasthenia gravis (JMG) were more likely to have enlarged thymus glands than younger girls and adults with myasthenia gravis (MG), according to a retrospective study in France. The higher levels of female hormones during puberty may explain these results, the researchers noted, supporting the potential…

The incidence and prevalence of myasthenia gravis (MG) among the population in France are higher than reported for other European countries. That’s according to a retrospective population-based study, which also found the incidence of MG tended to increase with age and was associated with a higher risk of cancer.

All United for MG has opened a petition in Europe supporting myasthenia gravis (MG) patient and caregiver rights, including those promoting a higher quality of life and access to better healthcare and resources. The petition hopes to gain momentum following Rare Disease Day in February and ahead of…

A treatment course of low-dose rituximab eased measures of clinical severity, improved quality of life, and allowed lower steroid doses to be used in myasthenia gravis (MG) patients who have antibodies against muscle-specific tyrosine kinase (MuSK). That’s according to a small study in China that looked at a…

Myasthenia gravis (MG) patients on long-term treatment with intravenous immunoglobulin (IVIg) or nonsteroidal immunosuppressants have significantly higher rates of disease crises and exacerbations, and subsequent greater healthcare costs, according to a retrospective analysis of insurance claims from a U.S. database. Overall, these findings highlight that treatments capable of…

Vyvgart (efgartigimod) generally is safe and leads to both significant symptom reductions and improvements in function in people with hard-to-treat generalized myasthenia gravis (gMG), according to a real-world, single-center study in the U.S. These results, the researchers say, “[provide] further support for the use of [Vyvgart] in clinical…

Myasthenia gravis (MG) caused by the presence of self-reactive antibodies targeting muscle-specific kinase (MuSK) affects mostly women in Japan, leading to generalized muscle weakness, particularly in the face and neck, a study reports. About half of 50 study patients had refractory MG, meaning they failed to respond to standard…